Sucralfate questions are classic “you either know the mechanism or you don’t” traps—because the stem often screams peptic ulcer disease, but the answer choices test whether you understand how each drug works, where it works, and what it messes up (drug interactions and toxicities included). Let’s break it down like a real Q-bank vignette and make every distractor pay rent.
Clinical Vignette (Q-Bank Style)
A 58-year-old man with osteoarthritis presents with 3 weeks of burning epigastric pain that worsens after meals and improves slightly with antacids. He has been taking high-dose ibuprofen daily for several months. He has stage 4 chronic kidney disease (eGFR 22 mL/min/1.73 m²). Upper endoscopy reveals a 1.5-cm duodenal ulcer with no active bleeding. The physician wants to start a medication that forms a protective barrier over the ulcer base to promote healing.
Which of the following is the most appropriate therapy?
A. Omeprazole
B. Bismuth subsalicylate
C. Misoprostol
D. Sucralfate
E. Famotidine
Correct answer: D. Sucralfate
Tag: GI > GI Pharmacology
Why Sucralfate Is Correct
Mechanism (the key phrase: “protective barrier over ulcer base”)
Sucralfate is a sucrose sulfate–aluminum hydroxide complex that, in an acidic environment, polymerizes and binds to exposed proteins in the ulcer crater.
- Requires acidic pH to work (important for interactions with PPIs/H2 blockers)
- Forms a physical barrier against:
- gastric acid
- pepsin
- bile salts
- Also promotes mucosal defenses (local increase in prostaglandins, bicarbonate, mucus)
High-yield uses
- Duodenal ulcers (especially when you want local mucosal protection)
- Stress ulcer prophylaxis is more often PPIs/H2 blockers in practice, but sucralfate is a classic exam option for “coat the ulcer.”
High-yield adverse effects
- Constipation (most common)
- Aluminum toxicity risk in renal failure (can accumulate)
- This is a board-relevant nuance: sucralfate contains aluminum → caution in advanced CKD.
Exam tip: If the stem mentions CKD, they may be testing whether you recognize the aluminum in sucralfate. Some questions still make sucralfate the best “barrier” answer despite CKD—because they’re testing mechanism recognition. Others will punish you for aluminum accumulation. Always read what the question is actually asking.
Drug interactions (very testable)
Sucralfate can decrease absorption of several drugs by binding them in the GI tract. Classic examples:
- Fluoroquinolones
- Tetracyclines
- Digoxin
- Phenytoin
- Levothyroxine
- Warfarin (less consistent but commonly tested)
Timing fix: Separate administration by at least 2 hours (often 2 hours before or 4–6 hours after, depending on the source/drug).
Quick Table: Sucralfate vs the Usual Ulcer Drugs
| Drug | Primary action | Best for | Key adverse effects | High-yield clue |
|---|---|---|---|---|
| Sucralfate | Coats ulcer base (local barrier) | Duodenal ulcers; mucosal protection | Constipation; aluminum toxicity in CKD | “Protective barrier,” “binds to ulcer crater” |
| PPI (e.g., omeprazole) | Irreversibly blocks H+/K+ ATPase in parietal cells | PUD, GERD, Zollinger-Ellison, H. pylori therapy | C. diff, pneumonia, hypomagnesemia, B12 deficiency | “Most potent acid suppression” |
| H2 blocker (famotidine) | Blocks H2 receptor on parietal cells → ↓ cAMP | Mild/moderate GERD, PUD | Confusion (elderly), rare CYP effects (cimetidine) | “Nighttime acid” |
| Misoprostol | PGE₁ analog → ↑ mucus/HCO₃⁻, ↓ acid | NSAID ulcer prophylaxis | Diarrhea; uterine contractions | “NSAID + ulcer prevention” |
| Bismuth subsalicylate | Mucosal coating + antimicrobial | H. pylori regimens; traveler’s diarrhea | Black stools/tongue; salicylate toxicity | “Black tongue/stool” |
Now: Why Each Distractor Is Wrong (and When It Would Be Right)
A. Omeprazole (PPI)
Why it’s tempting: NSAID-associated ulcers are very commonly treated with PPIs, and they’re excellent healing agents.
Why it’s wrong in this question: The question asks specifically for a drug that forms a protective barrier over the ulcer base. PPIs reduce acid production systemically; they do not “coat” the ulcer.
When omeprazole would be correct:
- Ongoing symptomatic PUD requiring potent acid suppression
- H. pylori treatment (in combination therapy)
- Prevention of recurrent NSAID-induced ulcers (often PPI is first-line in many real-world settings)
Step pearl: PPIs irreversibly inhibit the proton pump. They need active pumps → typically dosed before breakfast.
B. Bismuth subsalicylate
Why it’s tempting: It can coat mucosa and is used for ulcers in the context of H. pylori.
Why it’s wrong here: Bismuth is not the classic answer for “binds to the ulcer base” in Step-style pharmacology questions—that’s sucralfate. Also, bismuth is usually framed within H. pylori quadruple therapy.
When bismuth would be correct:
- H. pylori therapy (bismuth quadruple: PPI + bismuth + tetracycline + metronidazole)
- Traveler’s diarrhea symptom control
Step pearl: Black stools from bismuth can mimic melena—don’t get tricked.
C. Misoprostol
Why it’s tempting: NSAIDs are the big clue. Misoprostol is classically associated with NSAID-induced ulcers.
Why it’s wrong here: Misoprostol increases mucus and bicarbonate and decreases acid, but it’s not primarily a physical barrier drug. Also, the stem focuses on an existing ulcer and the specific mechanism of “protective barrier over ulcer base.”
When misoprostol would be correct:
- Prophylaxis for NSAID-induced ulcers (especially if high risk and must continue NSAIDs)
Step pearl (very testable):
- Misoprostol is a PGE₁ analog → uterine contraction and cervical ripening
- Contraindicated in pregnancy; adverse effect: diarrhea
E. Famotidine (H2 blocker)
Why it’s tempting: It treats ulcers by reducing acid and is a common alternative to PPIs.
Why it’s wrong here: Like PPIs, H2 blockers reduce acid secretion; they do not create a protective barrier.
When famotidine would be correct:
- Mild GERD/PUD symptoms
- Nocturnal acid suppression (H2 blockers can be useful for nighttime symptoms)
Step pearl: Cimetidine is the “problem child” (CYP inhibition, antiandrogen effects). Famotidine is cleaner.
High-Yield Takeaways (What You’re Actually Being Tested On)
Recognize sucralfate by its unique mechanism
- “Coats the ulcer” + “protective barrier” = sucralfate
- Works best in acidic environment → don’t pair too closely with strong acid suppressors if the question hints at decreased efficacy
Know the toxicity + interaction combo
- Constipation
- Aluminum accumulation in renal failure
- Binds other meds → decreased absorption (separate dosing)
Don’t miss the meta-skill: match the stem’s phrasing
If the question asks for:
- Acid suppression → think PPI/H2 blocker
- Mucosal protection / NSAID prophylaxis → think misoprostol (or PPI in many clinical contexts)
- Physical barrier at ulcer base → sucralfate
- H. pylori regimen clue → PPI + antibiotics ± bismuth
One-Liner Memory Hook
Sucralfate = “SUCrose + ALuminum” that sticks to the ulcer and SUCKS up other drugs (↓ absorption).
Frequently Asked Questions
What drug forms a protective barrier over a duodenal ulcer base?
Sucralfate forms a protective barrier over the ulcer base. It is a sucrose sulfate–aluminum hydroxide complex that polymerizes in an acidic environment and binds to exposed proteins in the ulcer crater. This creates a physical barrier against gastric acid, pepsin, and bile salts, while also supporting mucosal defenses through local increases in prostaglandins, bicarbonate, and mucus.
Why can chronic kidney disease matter when sucralfate shows up in an ulcer question?
Chronic kidney disease matters because sucralfate contains aluminum, which can accumulate in renal failure and lead to aluminum toxicity. This is a high-yield board nuance, especially in advanced CKD. Some questions still want sucralfate if they are specifically testing recognition of the barrier-forming mechanism, while others use CKD as a clue to avoid it, so the stem’s exact wording is crucial.
Why can sucralfate interfere with other medications?
Sucralfate can decrease absorption of other medications because it binds drugs in the gastrointestinal tract. Classic tested examples include fluoroquinolones, tetracyclines, digoxin, phenytoin, levothyroxine, and sometimes warfarin. To reduce this interaction, administration should be separated by at least 2 hours, with some sources recommending 2 hours before or 4 to 6 hours after depending on the drug.
How do you tell sucralfate from a PPI like omeprazole on a pharmacology question?
The key difference is that sucralfate coats the ulcer locally, while omeprazole suppresses acid production systemically. Sucralfate is the classic answer when the stem says a drug forms a protective barrier over the ulcer base or binds the ulcer crater. Omeprazole is instead identified by irreversible inhibition of the H+/K+ ATPase and is associated with potent acid suppression rather than physical coating.
What is the classic adverse effect of sucralfate?
Constipation is the classic and most common adverse effect of sucralfate. In addition to that routine side effect, sucralfate has the important board-relevant risk of aluminum toxicity in patients with renal failure because it contains aluminum. Those two clues together often help distinguish it from other ulcer medications in pharmacology questions.